CSBio CSBio

X
[{"orgOrder":0,"company":"Ncardia","sponsor":"Kiniciti","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ncardia"},{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Ardena"},{"orgOrder":0,"company":"Complix","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Complix Signs Agreement with I-Mab to Develop Cell Penetrating Alphabodies against 2 Intracellular Immuno-oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Complix"},{"orgOrder":0,"company":"Complix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Complix"},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments from Historical Shareholders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Celyad Oncology"},{"orgOrder":0,"company":"myNEO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"myNEO Evolves into myNEO Therapeutics to Reflect its New Strategy to Develop off-the-shelf Cancer Vaccine Immunotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"myNEO Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            CAMYO-01 is a novel off-the-shelf cancer vaccine, which is incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.

            Lead Product(s): CAMYO-01

            Therapeutic Area: Oncology Product Name: CAMYO-01

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 25, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA technology platform.

            Lead Product(s): B7-H6 Specific CAR T-cell Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Fortress Investment Group

            Deal Size: $10.5 million Upfront Cash: Undisclosed

            Deal Type: Private Placement August 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).

            Lead Product(s): Bisantrene

            Therapeutic Area: Oncology Product Name: RC220

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Race Oncology

            Deal Size: $1.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement July 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).

            Lead Product(s): iPSC-based Allogenic Cell Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Kiniciti

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership November 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proof-of-concept study showed the potential of Cell-Penetrating Alphabodies to efficiently penetrate the cancer cell membrane, disrupt an intracellular protein-protein interface, and cause an anti-tumor effect upon in vivo administration in relevant xenograft models.

            Lead Product(s): Cell-Penetrating Alphabodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets.

            Lead Product(s): Cell penetrating alphabodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: I-Mab Biopharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 10, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY